Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Clearmind Medicine (Nasdaq: CMND) has partnered with a leading government affairs consulting firm to advance psychedelic-based treatments in the healthcare sector. The collaboration aims to navigate regulatory landscapes and promote acceptance of psychedelic therapeutics among U.S. policymakers.
The company's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for Alcohol Use Disorder (AUD) at Yale School of Medicine and Johns Hopkins University. The partnership focuses on educating policymakers about psychedelics' therapeutic potential, particularly for treating conditions like PTSD and mental health disorders, while supporting the development of science-based regulatory frameworks.
Clearmind Medicine (Nasdaq: CMND) ha stretto una collaborazione con una rinomata società di consulenza in affari governativi per promuovere i trattamenti a base di sostanze psichedeliche nel settore sanitario. L'obiettivo della partnership è quello di orientarsi nel panorama normativo e favorire l'accettazione delle terapie psichedeliche tra i decisori politici statunitensi.
Il candidato principale dell'azienda, CMND-100, è attualmente in fase di trial clinici di Fase I/IIa per il Disturbo da Uso di Alcol (AUD) presso la Yale School of Medicine e la Johns Hopkins University. La collaborazione si concentra sull'educazione dei responsabili politici riguardo al potenziale terapeutico degli psichedelici, in particolare per il trattamento di patologie come il disturbo da stress post-traumatico (PTSD) e i disturbi mentali, sostenendo allo stesso tempo lo sviluppo di quadri normativi basati sulla scienza.
Clearmind Medicine (Nasdaq: CMND) se ha asociado con una destacada firma consultora en asuntos gubernamentales para impulsar tratamientos basados en psicodélicos en el sector de la salud. La colaboración busca navegar los marcos regulatorios y promover la aceptación de las terapias psicodélicas entre los legisladores de EE. UU.
El candidato principal de la compañía, CMND-100, está actualmente en ensayos clínicos de Fase I/IIa para el Trastorno por Consumo de Alcohol (AUD) en la Escuela de Medicina de Yale y la Universidad Johns Hopkins. La asociación se enfoca en educar a los responsables políticos sobre el potencial terapéutico de los psicodélicos, especialmente para tratar condiciones como el TEPT y trastornos de salud mental, apoyando al mismo tiempo el desarrollo de marcos regulatorios basados en la ciencia.
Clearmind Medicine (나스닥: CMND)는 의료 분야에서 사이키델릭 기반 치료법을 발전시키기 위해 주요 정부 업무 컨설팅 회사와 협력했습니다. 이번 협력은 규제 환경을 파악하고 미국 정책 입안자들 사이에서 사이키델릭 치료법의 수용을 촉진하는 것을 목표로 합니다.
회사의 주요 후보물질인 CMND-100은 현재 예일 의과대학과 존스 홉킨스 대학교에서 알코올 사용 장애(AUD)를 대상으로 1/2a상 임상시험을 진행 중입니다. 이번 파트너십은 PTSD 및 정신 건강 장애와 같은 질환 치료에 대한 사이키델릭의 치료 잠재력에 대해 정책 입안자들을 교육하고, 과학 기반의 규제 프레임워크 개발을 지원하는 데 중점을 두고 있습니다.
Clearmind Medicine (Nasdaq : CMND) s'est associé à un cabinet de conseil en affaires gouvernementales de premier plan pour faire progresser les traitements à base de psychédéliques dans le secteur de la santé. Cette collaboration vise à naviguer dans les cadres réglementaires et à promouvoir l'acceptation des thérapies psychédéliques auprès des décideurs politiques américains.
Le principal candidat de l'entreprise, CMND-100, est actuellement en cours d'essais cliniques de phase I/IIa pour le trouble lié à l'usage d'alcool (AUD) à la Yale School of Medicine et à l'Université Johns Hopkins. Le partenariat se concentre sur la sensibilisation des décideurs politiques au potentiel thérapeutique des psychédéliques, notamment pour traiter des affections telles que le PTSD et les troubles mentaux, tout en soutenant le développement de cadres réglementaires basés sur la science.
Clearmind Medicine (Nasdaq: CMND) hat sich mit einer führenden Regierungsberatung zusammengetan, um psychedelische Behandlungen im Gesundheitswesen voranzutreiben. Die Zusammenarbeit zielt darauf ab, regulatorische Rahmenbedingungen zu navigieren und die Akzeptanz psychedelischer Therapien bei US-Politikern zu fördern.
Der Hauptkandidat des Unternehmens, CMND-100, befindet sich derzeit in klinischen Phase I/IIa-Studien zur Behandlung der Alkoholgebrauchsstörung (AUD) an der Yale School of Medicine und der Johns Hopkins University. Die Partnerschaft konzentriert sich darauf, politische Entscheidungsträger über das therapeutische Potenzial von Psychedelika aufzuklären, insbesondere bei der Behandlung von Erkrankungen wie PTBS und psychischen Störungen, und unterstützt gleichzeitig die Entwicklung wissenschaftlich fundierter regulatorischer Rahmenwerke.
- Strategic partnership with prominent political consulting firm to navigate regulatory landscape
- Lead candidate CMND-100 advancing in Phase I/IIa clinical trials
- Trials being conducted at prestigious institutions (Yale and Johns Hopkins)
- Proactive approach to regulatory framework development
- Complex regulatory environment for psychedelic therapeutics
- Early clinical stage with no approved products yet
- Potential challenges in mainstream acceptance of psychedelic treatments
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a prominent government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments.
As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S.. The company’s partnered with the esteemed firm to support the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks.
“We are pleased to collaborate with a team of seasoned government affairs experts to help shape the future of psychedelic medicine,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “Psychedelics hold immense promise for transforming mental health treatment, but their novelty requires proactive engagement with regulators and policymakers to ensure safe and equitable access. This partnership underscores our commitment to driving progress in this rapidly evolving field.”
The consulting firm, known for its expertise in navigating federal and state regulatory environments, will work closely with Clearmind to educate policymakers on the therapeutic potential of psychedelics, support the development of balanced regulations, and foster strategic alliances to advance the company’s innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for AUD at prestigious institutions like Yale School of Medicine and Johns Hopkins University.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the purpose of Clearmind Medicine's (CMND) new partnership with the political consulting firm?
What stage is Clearmind Medicine's (CMND) lead drug candidate CMND-100 in development?
Which medical conditions is Clearmind Medicine (CMND) targeting with its psychedelic therapeutics?
Where are Clearmind Medicine's (CMND) clinical trials being conducted?
